Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabiae in Patients with Relapsed/Refractory AML

被引：0
|
作者：
Schimmer, Aaron D. [1 ]
Estey, Elihu H. [7 ]
Borthakur, Gautam [7 ]
Carter, Bing [7 ]
Schiller, Gary J. [2 ]
Tallman, Martin S. [3 ]
Altman, Jessica K. [3 ]
Karp, Judith E. [4 ]
Kassis, Jeannine [5 ]
Jacob, Christine [6 ]
Morris, Stephen [6 ]
Jolivet, Jacques [6 ]
Andreeff, Michael [7 ]
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada
[6] Aegera Therapeut Inc, Montreal, PQ, Canada
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：283 / 284
页数：2
相关论文
共 50 条
  • [21] Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
    Marcucci, G
    Byrd, JC
    Dai, GW
    Klisovic, MI
    Kourlas, PJ
    Young, DC
    Cataland, SR
    Fisher, DB
    Lucas, D
    Chan, KK
    Porcu, P
    Lin, ZP
    Farag, SF
    Frankel, SR
    Zvviebel, JA
    Kraut, EH
    Balcerzak, SP
    Bloomfield, CD
    Grever, MR
    Caligiuri, MA
    BLOOD, 2003, 101 (02) : 425 - 432
  • [22] Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
    Cortes, Jorge
    Kantarjian, Hagop
    Ball, Edward D.
    DiPersio, John
    Kolitz, Jonathan E.
    Fernandez, Hugo F.
    Goodman, Mark
    Borthakur, Gautam
    Baer, Maria R.
    Wetzler, Meir
    CANCER, 2012, 118 (02) : 418 - 427
  • [23] Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
    Konopleva, Marina Y.
    Dail, Monique
    Daver, Naval G.
    Garcia, Jacqueline S.
    Jonas, Brian A.
    Yee, Karen W. L.
    Kelly, Kevin R.
    Vey, Norbert
    Assouline, Sarit
    Roboz, Gail J.
    Paolini, Stefania
    Pollyea, Daniel A.
    Tafuri, Agostino
    Brandwein, Joseph M.
    Pigneux, Arnaud
    Powell, Bayard L.
    Fenaux, Pierre
    Olin, Rebecca L.
    Visani, Giuseppe
    Martinelli, Giovanni
    Onishi, Maika
    Wang, Jue
    Huang, Weize
    Dunshee, Diana R.
    Hamidi, Habib
    Ott, Marion G.
    Hong, Wan-Jen
    Andreeff, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (06): : 364 - 374
  • [24] Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)
    Advani, Anjali S.
    Li, Hongli
    Michaelis, Laura C.
    Medeiros, Bruno C.
    Liedtke, Michaela
    List, Alan F.
    O'Dwyer, Kristen
    Othus, Megan
    Erba, Harry P.
    Appelbaum, Frederick R.
    LEUKEMIA RESEARCH, 2018, 67 : 17 - 20
  • [25] Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs).
    Uy, Geoffrey L.
    Savona, Michael R.
    Tomlinson, Benjamin K.
    Carraway, Hetty
    Bixby, Dale L.
    Assouline, Sarit E.
    Brandwein, Joseph M.
    Levy, Moshe Yair
    Collins, Robert
    Lara-Guerra, Humberto
    Alters, Susan
    Eckert, Stephen
    Rowlinson, Scott
    Wooldridge, James
    Schimmer, Aaron David
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
    Chari, Ajai
    Larson, Sarah
    Holkova, Beata
    Cornell, Robert F.
    Gasparetto, Cristina
    Karanes, Chatchada
    Matous, Jeffrey V.
    Niesvizky, Ruben
    Valent, Jason
    Lunning, Matthew
    Usmani, Saad Z.
    Anderson, Larry D., Jr.
    Chang, Lipo
    Lee, Yihua
    Pak, Yvonne
    Salman, Zeena
    Graef, Thorsten
    Bilotti, Elizabeth
    Chhabra, Saurabh
    LEUKEMIA & LYMPHOMA, 2018, 59 (11) : 2588 - 2594
  • [27] Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
    Hua Jin
    Yu Zhang
    Sijian Yu
    Xin Du
    Na Xu
    Ruoyang Shao
    Dongjun Lin
    Yanqiu Chen
    Jie Xiao
    Zhiqiang Sun
    Lan Deng
    Xinquan Liang
    Hongyu Zhang
    Ziwen Guo
    Min Dai
    Pengcheng Shi
    Fen Huang
    Zhiping Fan
    Zhao Yin
    Li Xuan
    Ren Lin
    Xuejie Jiang
    Guopan Yu
    Qifa Liu
    Journal of Hematology & Oncology, 16
  • [28] A PHASE I TRIAL OF LENALIDOMIDE IN COMBINATION WITH INTERMEDIATE DOSE CYTARABINE (IDC) IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENTS
    Vigil, E.
    Griffiths, A.
    Thompson, E.
    Brady, E.
    Dickey, M.
    Ford, A.
    Wang, S.
    Wetzler, M.
    HAEMATOLOGICA, 2012, 97 : 33 - 33
  • [29] Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
    Jin, Hua
    Zhang, Yu
    Yu, Sijian
    Du, Xin
    Xu, Na
    Shao, Ruoyang
    Lin, Dongjun
    Chen, Yanqiu
    Xiao, Jie
    Sun, Zhiqiang
    Deng, Lan
    Liang, Xinquan
    Zhang, Hongyu
    Guo, Ziwen
    Dai, Min
    Shi, Pengcheng
    Huang, Fen
    Fan, Zhiping
    Yin, Zhao
    Xuan, Li
    Lin, Ren
    Jiang, Xuejie
    Yu, Guopan
    Liu, Qifa
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [30] PHASE 1B/2 PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) STUDY OF COMBINATION VORELOXIN AND CYTARABINE IN RELAPSED OR REFRACTORY AML PATIENTS
    Lancet, J.
    Roboz, G.
    Cripe, L.
    Karp, J.
    Berman, C.
    Hawtin, R.
    Chen, T.
    Fox, J.
    Michelson, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 342 - 343
12345